Graduate Institute of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan; Department of Chinese Medicine, Show Chwan Memorial Hospital, Changhua, 50008, Taiwan.
Graduate Institute of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan.
J Ethnopharmacol. 2020 Mar 1;249:112431. doi: 10.1016/j.jep.2019.112431. Epub 2019 Nov 26.
Sheng-Hua-Tang (SHT) is commonly used to treat female illnesses, especially postpartum conditioning. However, its effects and mechanisms on female reproductive system remain unclear. The aim of the present study was to investigate the effect of SHT on female brain-ovary-uterus axis from bench to clinic.
Mice were administrated SHT (200 mg/kg) orally for seven consecutive days. Brain, ovary, and uterus tissues were then collected for microarray analysis. A nationwide database analysis and a pilot randomized, open-label clinical trial were further applied to evaluate the clinical application and effects of SHT on postpartum women.
Microarray analysis showed that oral administration of SHT induced a cascade reaction of gene expression, with 17, 883, and 1592 genes were significantly regulated by SHT in brain, ovary, and uterus, respectively. Population-based analysis of one million subjects in Taiwan's National Health Insurance Research Database between 1997 and 2013 showed that SHT was commonly used in menstrual disorders in female population, especially dysmenorrhea, abnormal uterine bleeding, and variation of menstrual cycle. Clinical trial on postpartum women showed that oral administration SHT for one week alleviated uterine contraction pain and breast swelling pain. Furthermore, Mmp2, Mmp3, Mmp9, Mmp11, Mmp15, Oxtr, Plrl, and Tph2 gene expression affected by SHT in mice were correlated with clinical effects of SHT in human subjects.
This report provided the scientific evidences of mechanisms and clinical efficacies of SHT. Moreover, our findings might afford insights for clinical doctors in terms of SHT prescription.
圣华堂（SHT）常用于治疗女性疾病，尤其是产后调理。然而，其对女性生殖系统的影响和机制尚不清楚。本研究旨在从基础到临床研究 SHT 对女性脑-卵巢-子宫轴的影响。
小鼠连续 7 天口服 SHT（200mg/kg）。然后收集脑、卵巢和子宫组织进行微阵列分析。进一步进行全国性数据库分析和一项试点随机、开放标签临床试验，以评估 SHT 在产后妇女中的临床应用和效果。
微阵列分析显示，SHT 口服给药诱导基因表达级联反应，脑、卵巢和子宫中分别有 17、883 和 1592 个基因被 SHT 显著调控。对 1997 年至 2013 年台湾全民健康保险研究数据库中 100 万例患者进行的基于人群的分析显示，SHT 常用于女性人群的月经紊乱，尤其是痛经、异常子宫出血和月经周期变化。对产后妇女的临床试验表明，口服 SHT 一周可缓解子宫收缩痛和乳房肿胀痛。此外，SHT 影响的小鼠 Mmp2、Mmp3、Mmp9、Mmp11、Mmp15、Oxtr、Plrl 和 Tph2 基因表达与 SHT 在人体中的临床效果相关。
本报告提供了 SHT 的机制和临床疗效的科学证据。此外，我们的发现可能为临床医生开具 SHT 处方提供思路。
